Clinical Trials at Hartford Hospital
As of August 2026, 56 paid clinical trials are recruiting at Hartford Hospital, located at 80 SEYMOUR ST, HARTFORD, CT 06102-8000, phone (860) 696-6010 in Hartford, Connecticut. Active studies at this site cover conditions such as Neuroblastoma, Degenerative Disc Disease and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
56 clinical trials at Hartford Hospital
·Clear filters·A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Strategy for Improving Stroke Treatment Response
ELEVATE-HFpEF Clinical Study
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
FORWARD CAD IDE Study
PARTNER 3 Trial - Aortic Valve-in-Valve
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
MMA Embolization for Refractory Chronic Migraine
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
OssiMend BA in Posterolateral Instrumented Lumbar Fusion
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Common conditions studied in Hartford
- Neuroblastoma (8 active studies)
- Degenerative Disc Disease (6 active studies)
- Breast Cancer (5 active studies)
- Sickle Cell Disease (5 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Coronary Artery Disease (4 active studies)
Leading research sponsors in Hartford
- National Cancer Institute (NCI)
- Children's Oncology Group
- Connecticut Children's Medical Center
- SWOG Cancer Research Network
- Memorial Sloan Kettering Cancer Center
Frequently asked questions
How many paid clinical trials are currently recruiting in Hartford?
There are approximately 232 recruiting clinical trials in Hartford, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Hartford pay participants?
Most recruiting trials in Hartford compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Hartford?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Hartford?
The most common conditions under active study in Hartford include Neuroblastoma (8), Degenerative Disc Disease (6), Breast Cancer (5), Sickle Cell Disease (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Hartford?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Hartford on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Hartford?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Hartford?
Recruiting research sites in Hartford include Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Hartford right now?
The largest active categories in Hartford are Cancer & tumors (93), Cardiovascular (17), Neurology & pain (12). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Hartford Hospital?
Hartford Hospital is located at 80 SEYMOUR ST, HARTFORD, CT 06102-8000. Use the Google Maps link in the intro above to get directions.
How do I contact Hartford Hospital?
You can reach Hartford Hospital by phone at (860) 696-6010. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.